Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tramadol - Avenue Therapeutics

Drug Profile

Tramadol - Avenue Therapeutics

Alternative Names: AVE-901; IV tramadol - Revogenex/Avenue Therapeutics; RVX 109; Tramadol hydrochloride - Revogenex/Avenue Therapeutics; Tramadol intravenous - Revogenex/Avenue Therapeutics

Latest Information Update: 08 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revogenex
  • Developer Avenue Therapeutics
  • Class Anisoles; Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 04 Jan 2024 Avenue Therapeutics and the US FDA reaches final agreement on the study design and analysis approach of the phase III safety study for Tramadol (IV)
  • 25 Jul 2023 Avenue Therapeutics plans a phase III trial for Postoperative pain in 2023 (IV)
  • 25 Jul 2023 Avenue Therapeutics and the US FDA reaches agreement on the study design and analysis approach of the phase III safety study for intravenous tramadol
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top